Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Laura Dima"'
Publikováno v:
Pharmacology. 107:433-438
High-grade glioma (HGG) and glioblastoma are the most common adult malignant brain tumors. The standard treatment consists of surgical resection followed by radiochemotherapy with temozolomide. The prognosis and the therapeutic options of these malig
Autor:
Hiroaki Goto, Laura Dima, Steven G. DuBois, Ricarda Norenberg, Jordan R. Hansford, Esther De La Cuesta, Juneko E. Grilley-Olson, Ingrid Øra, David S. Hong, Theodore W. Laetsch, Karsten Nysom, Joanna Stefanowicz, Martin Højgaard, Valentina Boni, Hyoung Jin Kang, Julia C. Chisholm, Makoto Tahara, Birgit Geoerger, François Doz, Soledad Gallego-Melcon, David S. Ziegler, Alexander Drilon, Cornelis M. van Tilburg, Hyun Cheol Chung, Anne Thorwarth, Igor T. Gavrilovic, Antoine Italiano, Michael Capra, Sébastien Perreault, Nicolas U. Gerber
Publikováno v:
Neuro-Oncology. 24:997-1007
Background Larotrectinib is a first-in-class, highly selective tropomyosin receptor kinase (TRK) inhibitor approved to treat adult and pediatric patients with TRK fusion-positive cancer. The aim of this study was to evaluate the efficacy and safety o
Autor:
Liana Valeanu, Stefan Andrei, Carmen Ginghina, Cornel Robu, Adrian Ciurciun, Cosmin Balan, Mihai Stefan, Anca Stoian, Iulia Stanculea, Andreea Cheta, Laura Dima, Ovidiu Stiru, Daniela Filipescu, Serban‐Ion Bubenek‐Turconi, Dan Longrois
Publikováno v:
Microcirculation (New York, N.Y. : 1994)REFERENCES. 29(4-5)
Plasma viscosity is one of the critical factors that regulate microcirculatory flow but has received scant research attention. The main objective of this study was to evaluate plasma viscosity in cardiac surgery with respect to perioperative trajecto
Autor:
Xiuning Le, Christina Baik, Jessica Bauman, Jill Gilbert, Marcia S Brose, Juneko E Grilley-Olson, Tejas Patil, Ray McDermott, Luis E Raez, Jennifer M Johnson, Lin Shen, Makoto Tahara, Alan L Ho, Ricarda Norenberg, Laura Dima, Nicoletta Brega, Alexander Drilon, David S Hong
Publikováno v:
The Oncologist.
Background Larotrectinib is a first-in-class, highly selective, and central nervous system-active tropomyosin receptor kinase (TRK) inhibitor approved for the treatment of adult and pediatric patients with TRK fusion cancer. We report the efficacy an
Autor:
Alexander Drilon, Daniel S. W. Tan, Ulrik N. Lassen, Serge Leyvraz, Yongmei Liu, Jyoti D. Patel, Lee Rosen, Benjamin Solomon, Ricarda Norenberg, Laura Dima, Nicoletta Brega, Lin Shen, Victor Moreno, Shivaani Kummar, Jessica J. Lin
Publikováno v:
Drilon, A, Tan, D S W, Lassen, U N, Leyvraz, S, Liu, Y, Patel, J D, Rosen, L, Solomon, B, Norenberg, R, Dima, L, Brega, N, Shen, L, Moreno, V, Kummar, S & Lin, J J 2022, ' Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase Fusion–Positive Lung Cancers ', JCO Precision Oncology, vol. 6, e2100418 . https://doi.org/10.1200/PO.21.00418
PURPOSE Larotrectinib is a highly selective and CNS-active tropomyosin receptor kinase (TRK) inhibitor that has demonstrated efficacy across TRK fusion–positive cancers, regardless of the tumor type. The aim of this study was to assess the efficacy
Autor:
Alexander Drilon, Ezra Y. Rosen, Laura Dima, Dejan Juric, Antoine Italiano, N. Brega, John A. Reeves
Publikováno v:
Cancer Research. 81:PS11-06
Introduction: Larotrectinib is a first-in-class, CNS-active, highly selective tropomyosin receptor kinase (TRK) inhibitor approved by the US Food and Drug Administration and European Medicines Agency for the treatment of adult and pediatric patients
Autor:
Vlad Dumitru Baleanu, D Voiculescu, Catalin Lutic, Vasile D, Dragos Virgil Davitoiu, Laura Manda, Laura Dima
Publikováno v:
Research and Science Today. :75-84
Autor:
François Doz, Cornelis M van Tilburg, Birgit Geoerger, Karsten Nysom, Ingrid Øra, Valentina Boni, Julia Chisholm, Hyun Cheol Chung, Steven G DuBois, Soledad Gallego Melcón, Nicolas U Gerber, Hiroaki Goto, Juneko E Grilley-Olsen, Jordan R Hansford, David S Hong, Antoine Italiano, Hyoung Jin Kang, Michael Capra, Johannes H Schulte, Joanna Stefanowicz, Makoto Tahara, David S Ziegler, Igor T Gavrilovic, Ricarda Norenberg, Laura Dima, Esther De La Cuesta, Theodore W Laetsch, Alexander Drilon, Sébastien Perreault
Publikováno v:
Neuro-Oncology. 23:vi73-vi74
BACKGROUND NTRK gene fusions are oncogenic drivers in various CNS and non-CNS tumors. Larotrectinib is a first-in-class, highly selective TRK inhibitor approved for patients with TRK fusion cancer, with a 75% objective response rate (ORR) in 206 eval
Autor:
Makoto Tahara, J. Lin, Serge Leyvraz, A. Drilon, S. Kummar, Jordan Berlin, Liang Shen, R. Norenberg, Laura Dima, David S. Hong, N. Brega, Ulrik Lassen, Raymond S. McDermott, Marcia S. Brose, D.S.W. Tan, Jyoti D. Patel
Publikováno v:
Annals of Oncology. 32:S600-S601
Autor:
Ulrik Lassen, Laura Dima, John A. Reeves, David S. Hong, Alexander Drilon, Serge Leyvraz, Anna F. Farago, Benjamin Solomon, Jyoti D. Patel, Keunchil Park, Davendra Sohal, N. Brega
Publikováno v:
Neuro Oncol
BACKGROUND NTRK gene fusions occur in a range of tumor types, including those with CNS metastases. Larotrectinib, a highly selective FDA- and EMA- approved TRK inhibitor, demonstrated an objective response rate (ORR) of 79% across various cancers (Ho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c17d41158555203a10752e12626d40a5
https://europepmc.org/articles/PMC7650347/
https://europepmc.org/articles/PMC7650347/